Payment overview · 2025
General Payments
$290.38
16 reported records · 7 companies
Healthcare provider profile · identity verified
Mark A Wood, DO
Allopathic & Osteopathic Physicians|Family Medicine · GALION, OH · NPI 1356312110
Verified facts
What the public records show
CMS Open Payments records show Mark A Wood, DO received $290.38 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Viibryd by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.05 | 28.3% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.62 | 24.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.92 | 16.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.69 | 10.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.59 | 7.8% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $18.51 | 6.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.00 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $290.38 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $70.62 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.33 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $28.70 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 107 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 223 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIIBRYD open payments reported associated product |
CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050 |
Viibryd · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
223 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1175 | 211 |
| Potassium Chloride | Potassium Chloride | 985 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 905 | 180 |
| Furosemide | Furosemide | 901 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 792 | 113 |
| Eliquis | Apixaban | 723 | 88 |
| Sertraline Hcl | Sertraline Hcl | 612 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 578 | 112 |
| Lisinopril | Lisinopril | 561 | 115 |
| Trazodone Hcl | Trazodone Hcl | 535 | 86 |
| Gabapentin | Gabapentin | 531 | 90 |
| Buspirone Hcl | Buspirone Hcl | 453 | 67 |
| Omeprazole | Omeprazole | 430 | 90 |
| Metformin Hcl | Metformin Hcl | 419 | 77 |
| Losartan Potassium | Losartan Potassium | 410 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 390 | 82 |
| Carvedilol | Carvedilol | 389 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 376 | 78 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 66 |
| Mirtazapine | Mirtazapine | 321 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 65 |
| Pravastatin Sodium | Pravastatin Sodium | 287 | 64 |
| Prednisone | Prednisone | 275 | 127 |
| Donepezil Hcl | Donepezil Hcl | 274 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 273 | 50 |
| Montelukast Sodium | Montelukast Sodium | 272 | 58 |
| Famotidine | Famotidine | 269 | 59 |
| Allopurinol | Allopurinol | 252 | 40 |
| Sucralfate | Sucralfate | 246 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 237 | 33 |
| Simvastatin | Simvastatin | 237 | 49 |
| Jardiance | Empagliflozin | 223 | 28 |
| Baclofen | Baclofen | 219 | 44 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 219 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 193 | 82 |
| Warfarin Sodium | Warfarin Sodium | 188 | 32 |
| Cephalexin | Cephalexin | 187 | 108 |
| Memantine Hcl | Memantine Hcl | 177 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 41 |
| Pioglitazone Hcl | Pioglitazone Hcl | 158 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 154 | 22 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 146 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 140 | 25 |
| Atenolol | Atenolol | 138 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 136 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 128 | 26 |
| Bupropion Xl | Bupropion Hcl | 127 | 26 |
| Levofloxacin | Levofloxacin | 126 | 78 |
| Tramadol Hcl | Tramadol Hcl | 126 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 22 |
| Januvia | Sitagliptin Phosphate | 115 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 114 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 112 | 17 |
| Farxiga | Dapagliflozin Propanediol | 107 | 16 |
| Myrbetriq | Mirabegron | 106 | 12 |
| Spironolactone | Spironolactone | 106 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 22 |
| Finasteride | Finasteride | 104 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 41 |
| Cefuroxime | Cefuroxime Axetil | 94 | 57 |
| Levetiracetam | Levetiracetam | 94 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 23 |
| Glimepiride | Glimepiride | 89 | 16 |
| Meloxicam | Meloxicam | 88 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 87 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 14 |
| Ezetimibe | Ezetimibe | 85 | 19 |
| Divalproex Sodium | Divalproex Sodium | 84 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 27 |
| Bupropion Hcl Sr | Bupropion Hcl | 80 | 15 |
| Lorazepam | Lorazepam | 80 | 11 |
| Topiramate | Topiramate | 80 | 14 |
| Midodrine Hcl | Midodrine Hcl | 79 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 12 |
| Fluconazole | Fluconazole | 75 | 39 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 33 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 12 |
| Lamotrigine | Lamotrigine | 73 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 73 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 70 | 39 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 69 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 69 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 68 | 16 |
| Ozempic | Semaglutide | 68 | 12 |
| Tradjenta | Linagliptin | 66 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 18 |
| Pregabalin | Pregabalin | 65 | 17 |
| Clonazepam | Clonazepam | 64 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 19 |
| Ertapenem | Ertapenem Sodium | 61 | 25 |
| Meclizine Hcl | Meclizine Hcl | 61 | 15 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 61 | suppressed |
| Trulicity | Dulaglutide | 60 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 59 | 31 |
| Alprazolam | Alprazolam | 59 | 19 |
| Lovastatin | Lovastatin | 59 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 58 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 58 | 22 |
| Metoclopramide Hcl | Metoclopramide Hcl | 58 | suppressed |
| Ondansetron Odt | Ondansetron | 57 | 37 |
| Venlafaxine Hcl | Venlafaxine Hcl | 53 | suppressed |
| Nifedipine Er | Nifedipine | 51 | suppressed |
| Olanzapine | Olanzapine | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 49 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 49 | 18 |
| Risperidone | Risperidone | 49 | suppressed |
| Cimetidine | Cimetidine | 48 | suppressed |
| Lactulose | Lactulose | 48 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 19 |
| Latanoprost | Latanoprost | 46 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 14 |
| Kerendia | Finerenone | 45 | suppressed |
| Nystatin | Nystatin | 44 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | 13 |
| Calcitriol | Calcitriol | 41 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Cholestyramine Light | Cholestyramine | 41 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 22 |
| Novolog | Insulin Aspart | 38 | 11 |
| Scopolamine | Scopolamine | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Bumetanide | Bumetanide | 37 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 37 | suppressed |
| Nyamyc | Nystatin | 37 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 22 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 34 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Cefdinir | Cefdinir | 32 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 32 | suppressed |
| Colchicine | Colchicine | 31 | 12 |
| Nitroglycerin | Nitroglycerin | 31 | 21 |
| Novolog Flexpen | Insulin Aspart | 31 | 13 |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Anastrozole | Anastrozole | 29 | suppressed |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Metolazone | Metolazone | 29 | 14 |
| Auryxia | Ferric Citrate | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Rayaldee | Calcifediol | 28 | suppressed |
| Humalog | Insulin Lispro | 27 | 11 |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 19 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | suppressed |
| Acetic Acid | Acetic Acid | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 20 |
| Budesonide | Budesonide | 25 | suppressed |
| Clonidine | Clonidine | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Trimethoprim | Trimethoprim | 25 | suppressed |
| Victoza 3-Pak | Liraglutide | 25 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 24 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Austedo | Deutetrabenazine | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 14 |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Imipenem-Cilastatin Sodium | Imipenem/Cilastatin Sodium | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Viibryd | Vilazodone Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | 16 |
| Methimazole | Methimazole | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 14 |
| Nystop | Nystatin | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Caplyta | Lumateperone Tosylate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Linezolid | Linezolid | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Loxapine | Loxapine Succinate | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $290.38 · 16 records | Lilly USA, LLC | BREZTRI, FARXIGA, GVOKE HYPOPEN, JARDIANCE, LEQVIO, MOUNJARO, Natroba, Spinosad, VOQUEZNA, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error